<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Dogukan Dinc on Medium]]></title>
        <description><![CDATA[Stories by Dogukan Dinc on Medium]]></description>
        <link>https://medium.com/@dogukan.dinc?source=rss-d29e23a4b0dd------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*uAqy60Ed8g4CHCteI5JZaQ.jpeg</url>
            <title>Stories by Dogukan Dinc on Medium</title>
            <link>https://medium.com/@dogukan.dinc?source=rss-d29e23a4b0dd------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 14:41:05 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@dogukan.dinc/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Bankalar nasıl para kazanır?]]></title>
            <link>https://medium.com/@dogukan.dinc/bankalar-nas%C4%B1l-para-kazan%C4%B1r-492efcba3dad?source=rss-d29e23a4b0dd------2</link>
            <guid isPermaLink="false">https://medium.com/p/492efcba3dad</guid>
            <category><![CDATA[asset-management]]></category>
            <category><![CDATA[finance]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[banking]]></category>
            <category><![CDATA[balance-sheet]]></category>
            <dc:creator><![CDATA[Dogukan Dinc]]></dc:creator>
            <pubDate>Sun, 12 May 2024 17:35:05 GMT</pubDate>
            <atom:updated>2024-05-12T18:49:16.465Z</atom:updated>
            <content:encoded><![CDATA[<p>Bankalar belki de ekonomik sistem içerisindeki en kritik kurumlar. Zira para arzının ve fiyatlarının son kullanıcıya ulaştığı nihai işletmeler onlar. Merkez Bankası tarafından belirlenen para politikasının topluma ulaşması konusunda itici güçler. Peki hiç bankaların nasıl para kazandıklarını düşündünüz mü? Genelde banka denildiğinde insanların aklına sınırsız para kaynağına sahip kötü kurumlar geliyor olabilir. Diledikleri gibi para yaratabilen ve bu para ile insanların hayatına el koyan açgözlü canavarlar da olabilirler. Ama genel kanının aksine bankaların kimsenin hayatına “çökmek” gibi bir derdi yok. Onlar da aslında diğer ekonomik birimler gibi ticaret yapıyorlar. Sundukları ürün de para…</p><p>Şimdi varsayalım benim herhangi bir ihtiyacım için 1.000.000 TL civarında bir paraya ihtiyacım olsun. Bu parayı nasıl temin edebilirim? Öncelikle arkadaşlarıma veya akrabalarıma gidebilirim, veya tefecilerden para isteyebilirim. Bu sayede elime bir miktar para geçmiş olur. Peki ödeme sistemi ya da faizi ne olacak? Ya da daha doğrusu bu borcu ödeyecek miyim yoksa ödemeyecek miyim kim bilecek? İşte ikili bir para alışverişinde insanların ve şirketlerin yaşayacağı temel sorunlardan birkaç tanesi bunlar. Yani gün sonunda nihai olarak birilerinin fon talebi, birilerinin de fon arzı olacak. Bunu reddetmek veya kaçınmak doğru bir yaklaşım değil. Peki birileri bizim için para toplasa, ihtiyacımız olduğunda gidip çeksek ve bizler için ödeme planları oluşturup paranın fiyatını belirlese çok güzel olmaz mıydı? Olurdu ve oldu da. Bankalar günümüzde tam olarak bunu yapıyor.</p><h3>“Güven satmak”</h3><p>Kredi kelimesinin kökeni esasen güven ve itibar anlamına gelir. Yani kredi dediğimizde aklımızda canlanması gereken ilk kelime güvendir. Bu durumda kredi kullanmak aslında banka nezdinde güven kullanmak demektir. Sizin paranız veya teminatınız olmasa dahi finansal sistemde elde etmiş olduğunu bir güven varsa paranız da vardır. Buradan paranın aslında kredi olduğuna ulaşabiliriz. Diğer bir deyişle para aslında güvendir. Bugün kredi notunuz en basit tabirle finansal sistemin gözünden sizin değerinizi ortaya koyar.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/320/1*CIXJiZeUTz2zGsqystt1Ug.jpeg" /></figure><h3>Banka Bilançosu</h3><p>Bankaların bilançoları rutin işletme bilançolarından bayağı farklıdır. Aşağıda örnek olması açısından standart bir bilanço örneği ekliyorum.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/515/1*ea7R_lPQwYi38t_zJ_Fl0Q.png" /><figcaption>Standart bir işletme bilançosu</figcaption></figure><p>Bu basit bilançoda:</p><ul><li>Varlıklar: İşletmenin sahip olduğu kaynaklar listelenir. Nakit, alacaklar (müşterilerden tahsil edilecek tutarlar), stoklar (ürünlerin veya malzemelerin değeri), maddi duran varlıklar (makine, bina vb.) ve diğer varlıklar (yatırım, patentler vb.) gibi unsurları içerebilir.</li><li>Yükümlülükler ve Özkaynak: İşletmenin borçları (kısa ve uzun vadeli borçlar, diğer yükümlülükler) ve özkaynak (şirketin sahiplerine ait hisseler ve birikmiş karlar) listelenir.</li></ul><p>Bilanço, işletmenin finansal durumunu belirli bir tarihte gösterir. Varlıklar, yükümlülükler ve özkaynak arasındaki dengeyi korur.</p><p>Şimdi de farkın daha iyi anlaşılması için banka bilançosu örneği ekliyorum.</p><figure><img alt="Banka bilançosu" src="https://cdn-images-1.medium.com/max/523/1*pTMXPYXwsYiva9PdI0Wj2A.png" /><figcaption>Banka bilançosu</figcaption></figure><p>Bu banka bilançosu örneğinde:</p><ul><li>Varlıklar: Bankanın elindeki kaynaklar listelenir. Nakit, kredi portföyü (verilen kredilerin toplam değeri), yatırım menkul kıymetleri (hazine bonoları ve tahviller vb.), maddi duran varlıklar (ofis binaları, banka ekipmanları vb.) ve diğer varlıklar (ticari gayrimenkuller, lisanslar vb.) gibi unsurları içerebilir.</li><li>Yükümlülükler ve Özkaynak: Bankanın borçları (müşterilerin mevduatları, borçlanma vb.) ve özkaynak (bankanın hisse senetleri, öz sermaye gibi) listelenir.</li></ul><p>Temel farkları şu şekilde sıralayabiliriz.:</p><ol><li>Kredi Portföyü: Bankaların varlıkları arasında kredi portföyü bulunur. Bu, bankanın müşterilere verdiği kredilerin toplam değerini ifade eder. Bu, sıradan bir işletmenin bilançosunda bulunmaz.</li><li>Mevduatlar: Bankaların en büyük yükümlülükleri arasında müşterilerden topladıkları mevduatlar bulunur. Bu, sıradan bir işletmenin bilançosunda genellikle bulunmaz.</li></ol><p>Bankaların bilançoları, mevduat toplama ve kredi verme gibi özel faaliyetleri yansıtırken, sıradan bir işletmenin bilançosu, genellikle üretim, satış ve varlık yönetimi gibi daha genel iş faaliyetlerini yansıtır.</p><blockquote>Banka bilançosunu anlamak bankacılığı anlamak için oldukça elzemdir. Hatta bankaların sırf bilançolarını takip etmek için mali işler departmanının haricinde bilanço yönetimi ile aktif-pasif yönetimi gibi birimleri bulunur. Bunlara ek bankalarda bilanço stratejilerini belirmek için Aktif-Pasif Komitesi (ALCO) belirli aralıklarla toplanır.</blockquote><h3>Peki bankalar ne iş yapar?</h3><p>Bankalar, genellikle müşterilerinden mevduat toplayarak ve kredi vererek para kazanırlar. İşleyişlerini basitçe özetlersek:</p><ol><li>Mevduat Toplama: Bankalar, bireylerden, işletmelerden ve diğer kuruluşlardan mevduat kabul ederler. Bu, müşterilerin bankaya para yatırması anlamına gelir. Mevduatlar, çeşitli hesap türlerinde (vadeli mevduat, vadesiz hesaplar vb.) tutulur.</li><li>Kredi Verme: Bankalar, mevduat topladıkları paraları kredi olarak müşterilere vererek kazanç elde ederler. Krediler genellikle bireylerin konut, araba gibi büyük satın alımlarını finanse etmek veya işletmelerin yatırım yapmasını sağlamak için kullanılır.</li><li>Faiz Geliri: Bankalar, aldıkları kredilerden daha yüksek faiz oranlarıyla mevduat sahiplerine faiz öderler ve kredilere daha düşük faiz oranları uygularlar. Bu fark, bankaların kâr elde ettiği ana kaynaktır. <strong>Bu kısım önemli çünkü dananın kuyruğunun koptuğu kısım burası.</strong></li></ol><p>Banka, varlıkları ile yükümlülükleri arasındaki dengenin korunmasına dikkat eder. Genellikle likit varlıklar, kısa vadeli yükümlülüklerden daha fazla olmalıdır, böylece banka likiditeyi sağlayabilir ve olası risklere karşı korunabilir. Bu, bankanın sağlam bir finansal yapıya sahip olmasını sağlar.</p><h3>Net Faiz Geliri (Net Interest Income)</h3><p>Net faiz geliri, bir bankanın faiz gelirleri ile faiz giderleri arasındaki farktır. Bankalar, müşterilerine kredi verirken faiz alır ve müşterilerinden aldıkları mevduatlara faiz öderler. Net faiz geliri, bu faiz gelirleri ile faiz giderleri arasındaki farkı gösterir ve bankanın kredi ve mevduat faaliyetlerinden elde ettiği net karı temsil eder.</p><p>Örneklerle verecek olursak:</p><ol><li>Faiz Gelirleri: Bankalar, kredi verdikleri zaman müşterilerinden faiz geliri elde ederler. Örneğin, bir banka bir müşteriye 100.000 TL kredi verir ve bu kredi için %10 faiz alırsa, yıllık faiz geliri 10.000 TL olur.</li><li>Faiz Giderleri: Bankalar, müşterilerinden topladıkları mevduatlara faiz öderler. Örneğin, bir banka müşterilerinden toplam 200.000 TL mevduat toplar ve bu mevduatlara %5 faiz öderse, yıllık faiz gideri 10.000 TL olur.</li></ol><p>Net faiz geliri hesaplanırken bu iki rakam arasındaki fark alınır:</p><p>Net Faiz Geliri= Faiz Gelirleri (Kredilerden gelen faiz) — Faiz Giderleri (Mevduatlara ödenen faiz)</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/424/1*RmmGZecpSGZ85rWQjo83ig.png" /><figcaption>Faiz geliri mekanizması (basitleştirilmiş)</figcaption></figure><p>Örneğimizde, faiz gelirleri 10.000 TL ve faiz giderleri de 10.000 TL olduğu için net faiz geliri 0 TL olur. Ancak genellikle faiz gelirleri faiz giderlerinden yüksek olduğu için bankalar net bir faiz geliri elde ederler.</p><p>Bu net faiz geliri, bankanın başka giderlerini karşılamak ve kâr elde etmek için kullanılır. Bu şekilde, bankalar kredi vererek ve müşterilerinden mevduat toplayarak net faiz geliri aracılığıyla para kazanırlar.</p><p>İlerleyen yazılarda FTP mekanizmasına ve günümüzde bankaların faiz geliri mekanizmasını nasıl daha efektif kıldığına değineceğim. Sağlıcakla…</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=492efcba3dad" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Yatırımları Değerlendirmek: Sharpe Rasyosu]]></title>
            <link>https://medium.com/@dogukan.dinc/yat%C4%B1r%C4%B1mlar%C4%B1-de%C4%9Ferlendirmek-sharpe-rasyosu-8d2596c8ab1b?source=rss-d29e23a4b0dd------2</link>
            <guid isPermaLink="false">https://medium.com/p/8d2596c8ab1b</guid>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[finance]]></category>
            <category><![CDATA[risk-management]]></category>
            <category><![CDATA[economics]]></category>
            <dc:creator><![CDATA[Dogukan Dinc]]></dc:creator>
            <pubDate>Sat, 27 Apr 2024 20:00:41 GMT</pubDate>
            <atom:updated>2024-04-29T05:57:16.868Z</atom:updated>
            <content:encoded><![CDATA[<p>Modern toplumdaki rasyonel bireyler, miktarından bağımsız olarak, gelirlerinin bir kısmı ile veya ellerinde hazır olan parayı değerlendirmek üzere farklı yatırım kaynaklarına yönelmekte. Hisse senetleri, tahvil, bono, mevduat, emtialar ve yatırım fonları gibi araçlar çoğu için bu amaç doğrultusunda kullanılan araçlar. Bu araçlar, birikimler ve planlar çevresinde hayali kurulan emeklilik veyahut konut için oldukça faydalı bir sistem sunuyor. Uzun vadeli yatırımları teşvik eden BES gibi alanların da yaygınlaşması ile beraber portföy yönetimi son yılların yükselen konusu. Elbette ki portföy yönetimi denildiğinde çoğu kişinin aklına getiri ve kâr gelmekte. Ancak çoğunluğun gözardı ettiği risk ile alternatif getiri gibi konular maalesef yatırım kararları alırken önemsizmiş gibi görülebiliyor. Bu yazıda sizlere risk, getiri ve alternatif getiri gibi konulardan bahsedeceğim. Tabii ki tüm bunları nasıl analiz edebileceğimizi de…</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*wdHMmdscUKM96LvaIRL0og.jpeg" /></figure><p>Bir yatırım yapmadan önce birçok yatırımcı bahsi geçen menkul kıymetteki fiyat hareketlerini inceler. Bu fiyat hareketleri birçoğu için doğru yatırımın anahtarıdır. Fiyatlar incelenirken fiyatların ötesindeki doğru verileri görebilmek gerekli. Örneğin herhangi bir hisse senedinin pay başına fiyatlarını aşağıdaki gibi varsayalım:</p><p><strong>Pazartesi: 110 TL</strong></p><p><strong>Salı: 112 TL</strong></p><p><strong>Çarşamba: 111 TL</strong></p><p><strong>Perşembe: 115 TL</strong></p><p><strong>Cuma: 121 TL</strong></p><p>A isimli yatırımcı, eğer pazartesi günü bahsi geçen pay senedini alıp cuma günü satmış olsaydı 11 TL kâr elde edecekti. Hatta biraz daha ileri gidip 121 / 110 — 1 diyerek 10% kâr yakaladığını da görebilir. Böyle durumlarda çoğunlukla gözden kaçan birkaç husus var. Örneğin bir getiriyi analiz ederken sadece alış ve satış rakamlarını inceleyerek ortalama getiriyi göz ardı etmiş oluyoruz.</p><p>Mesela, aynı işlemi yapan B isimli yatırımcı ortalama getiriyi şu şekilde hesaplamış olsun:</p><p>112 / 110–1 = 1.82 %</p><p>111 / 112–1 = -0.89%</p><p>115 / 111–1 = 3.6%</p><p>121 / 115–1 = 5.22%</p><p>Ardından tüm bu getirilerin aritmetik ortalamasını alarak ortalama getiriyi 2.44% bulmuş olurdu. Bunun ardından biraz daha ileri giderek bileşik getiriyi hedeflemiş olduğunda, ((1+0.0244)⁴)-1 formülünden de ulaşabileceğimiz gibi 4 günlük bileşik getirisini yaklaşık 10.12% olarak hesaplardı.</p><p>Bu durumda Yatırımcı A, 4 günlük getirisini %10 hesaplarken yatırımcı B %10.12 getiri sağlayabileceğini görürdü. Bu hesap aklımızda kalsın zira yatırım yaparken sadece getiri yönlü bakmamayı göstermek için güzel bir örnek.</p><p>Yatırımcı B, attığım taş ürküttüğüm kuşa değdi mi acaba diyerek yatırım ekseni boyunca aldığı riski de hesaplamak istesin. Yatırım yönetiminde risk, getirilerin ne kadar oynak olduğu ile ilgilidir. Yani kabaca ortalamada günde %10 kazandırıp ertesi gün %9 kaybettiren bir menkul kıymet, bir günde %2 kazandırıp diğer gün %2.2 kazandıran bir menkul kıymetten daha risklidir. Peki kantitatif olarak riski nasıl ölçebiliriz? Burada da bizlerin yardımına her zaman olduğu gibi istatistik bilimi koşuyor. Volatiliteyi de ölçmek için kullandığımız varyans terimi üzerinden katlanmış olduğumuz riski sayısallaştırmak mümkün. Bu kısımda formüller ile aklınızı bulandırmak istemem o yüzden kısa geçeceğim.</p><p>Bahsi geçen yatırımın riskini gün gün veya hafta hafta hesapladığımız ((t/ t-1) -1) getirilerin standart sapmasını bularak hesaplayabiliriz. Örneğimizde getirilerin standart sapması 2.62% olarak hesaplanmakta.</p><h3>Peki bu yatırım ne derece kârlı buna bakabilir miyiz? Tabii ki!</h3><p>Değişim katsayısı (coefficient of variation) kullanarak yatırımlarımızı diğer yatırımlar ile kıyaslayıp ortalama getiri ve standart sapmayı kullanarak ilerleyebiliriz. Değişim katsayısını hesaplamak çok basit. Risk/Getiri veya Standart Sapma / Ortalama Getiri üzerinden hesaplayabiliriz. Örneğimizdeki değişim katsayısı 0.0262 / 0.1012 formülü ile 25.86% olarak bulunabilir. Takdir edeceğiniz üzere bu yöntem rakamsal olarak pek bir anlam taşımıyor. Bu rakamı anlamlandırmak için birden fazla yatırım alternatifi arasından seçmek daha kıymetli. Bu rakam anlam ifade etmiyor tamam ama daha anlamlı bir rakam yok mu diyorsanız burada Sharpe rasyosu karşımıza çıkıyor.</p><blockquote>Sharpe rasyosu, Amerikalı ekonomist William Forsyth Sharpe tarafından ortaya konuldu. Sharpe oranı, yatırımcıların hedefledikleri yatırımların risklerini değerlendirmek için kullanılırken piyasa uzmanları, yatırımlarının potansiyel getirilerini değerlendirmek ve hesaplamak için bu oranı sıkça kullanır. Herhangi bir yatırımın, risksiz yatırımların getiri ölçüleri ve oranlarına göre ne kadar iyi bir performans gösterebileceği, Sharpe oranı ile belirlenir.</blockquote><p>Sharpe oranı, risk primini belirlemek için risk içermeyen yatırımların getirileriyle karşılaştırılır. Ek getiri veya risk primi, risksiz orandan çıkarılarak hesaplanır. Sharpe oranı, performansı ölçmek için sıkça kullanılan bir araçtır, ancak bazı sınırlamalara sahiptir. Örneğin, yatırım getirilerinin normal dağılım gösterdiği varsayılır, ancak bu her zaman geçerli değildir. Ayrıca, Sharpe oranı herhangi bir yatırımın aşağı yönlü risklerini tam olarak yansıtmaz. Yatırımcılar, bir varlığın risklerini göze alıp almayacağını belirlemek için Sharpe oranını kullanır. Teknik olarak, Sharpe oranı, risksiz orandan sapmalar karşısında elde edilen ortalama getiri olarak hesaplanır. Bu nedenle, iki farklı varlık arasında yapılan bir karşılaştırmada, daha yüksek bir Sharpe oranına sahip olan varlık daha iyi bir yatırım olarak kabul edilir. Bu oran risk içermeyen getiri oranının yatırımın getirisinden çıkarılması ve sonrasında bu sayının yatırım getirilerinin standart sapmasına bölünmesi ile hesap edilir.</p><p>Sharpe rasyosuna ait formül aşağıdaki gibidir:</p><p>Sharpe Rasyosu = (Ortalama getiri — Risksiz getiri) / (Standart Sapma)</p><p>Buradaki risksiz getiri dediğimiz olgu göreceli olup genelde piyasadaki risksiz yatırımlardan elde edebileceğimiz alternatif getiriye işaret eder. Örneğin devlet tahvillerine ait getiriler gibi.</p><p>Örneğimiz için Sharpe oranını hesaplayalım, örneğimizde risksiz getiri oranı belirlenen aralık için 0.0060 olsun.</p><p>Sharpe Rasyosu = (0.1012 – 0.0060) / (0.0262) = 3.6375</p><p>Piyasada kabul görmüş haliyle bu oranı yorumlamak daha kolaydır:</p><ul><li>1’in altında olan oranlar: Yetersiz</li><li>1’den yüksek oranlar: Kabul edilebilir</li><li>2’den yüksek oranlar: Çok iyi</li><li>3 ya da daha yüksek oranlar: Mükemmel</li></ul><p>Bizim örneğimizde elde ettiğimiz 3.63 oranı bu hisse senedine ait belirli zaman ekseninde mükemmel bir Sharpe rasyosuna işaret ediyor. Elbette ki yatırım kararları için geçmiş zaman ufkunu 5 gün ile sınırlı tutmak doğru değil ancak örneğimiz için güzel bir örneklem olduğunu düşünüyorum.</p><p>Bir sonraki yazımda Sortino oranından ve geometrik ortalama gibi daha sofistike yöntemlerden bahsedeceğim.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8d2596c8ab1b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Importance of Patents and Innovation in the Pharmaceutical Industry]]></title>
            <link>https://medium.com/@dogukan.dinc/the-importance-of-patents-and-innovation-in-the-pharmaceutical-industry-4c92f85913f1?source=rss-d29e23a4b0dd------2</link>
            <guid isPermaLink="false">https://medium.com/p/4c92f85913f1</guid>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[pharmacy]]></category>
            <category><![CDATA[pharmaceuticals-industry]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[pharma]]></category>
            <dc:creator><![CDATA[Dogukan Dinc]]></dc:creator>
            <pubDate>Sun, 07 May 2023 12:50:33 GMT</pubDate>
            <atom:updated>2023-05-07T12:53:34.924Z</atom:updated>
            <content:encoded><![CDATA[<h3><em>Introduction</em></h3><p>Patents are legal tools that protect innovative companies’ products, encouraging innovation. In the pharmaceutical industry, patents hold strategic importance by limiting market entry and competition for a specific period. During this time, they help innovative companies protect their investments, recover their costs, and fund future research and development activities.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/700/0*tqtMnN-hrzbLR7ZI.jpeg" /></figure><p>The pharmaceutical sector in Turkey plays a vital role in providing healthcare solutions to its population and contributing to the country’s economy. With a strong emphasis on research and development, manufacturing capabilities, and domestic production, Turkey has emerged as a significant player in the regional pharmaceutical industry. In this article, we will explore the general features of the pharma sector in Turkey, including key players, regulations, research and development activities, and market dynamics.</p><h3>Key Players in the Turkish Pharma Sector</h3><p>Pharmaceutical Companies: Turkey boasts a diverse range of pharmaceutical companies, both local and international. Leading companies include Abdi İbrahim, Sanofi, and Novartis Pharmaceuticals. International pharmaceutical companies also have a significant presence in the market, contributing to innovation, research, and access to global resources.</p><blockquote><em>Turkish Medicines and Medical Devices Agency (TMMDA): The TMMDA, known as TİTCK in Turkish, is the regulatory authority responsible for overseeing the pharmaceutical sector. It ensures compliance with safety, efficacy, and quality standards, as well as granting marketing authorizations for pharmaceutical products.</em></blockquote><p>Turkish Pharmacists’ Association (TPA): The TPA represents pharmacists across the country and plays a critical role in ensuring the safe and responsible distribution of pharmaceutical products. It promotes professional standards, ethical practices, and patient education.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/700/0*SqMo6z02XYxDVJ1b.jpeg" /></figure><h3>Regulatory Environment</h3><p>The regulatory environment in Turkey’s pharma sector is governed by laws and regulations to ensure patient safety, drug quality, and fair market practices. Key aspects of the regulatory landscape include:</p><blockquote><em>Marketing Authorization: Pharmaceutical companies must obtain marketing authorization from the TMMDA to market and distribute their products in Turkey. The authorization process involves comprehensive evaluations of safety, efficacy, and quality data.</em></blockquote><p>Pricing and Reimbursement: The Pricing and Reimbursement Authority (SDP) determines the pricing and reimbursement policies for pharmaceutical products in Turkey. These policies aim to strike a balance between patient access and cost containment.</p><p>Intellectual Property Rights: Intellectual property protection is crucial for incentivizing innovation. Turkey has a legal framework in place to protect patents, trademarks, and copyrights, ensuring that pharmaceutical companies’ intellectual property rights are respected.</p><h3>Research and Development Efforts</h3><p>Research and development (R&amp;D) activities are integral to the growth and innovation of the Turkish pharma sector. Key aspects of R&amp;D in Turkey include:</p><blockquote><em>Public and Private Collaboration: Collaboration between academic institutions, research centers, and pharmaceutical companies is encouraged to foster R&amp;D activities. Universities play a significant role in conducting research, while private companies provide resources and expertise for drug development.</em></blockquote><p>Technology Transfer and Licensing: Turkish pharma companies often collaborate with international partners for technology transfer, licensing agreements, and joint research projects. These collaborations enhance knowledge sharing, access to innovative technologies, and accelerated drug development.</p><h3>Market Dynamics</h3><p>The Turkish pharmaceutical market is characterized by a combination of domestic production and imports. Key market dynamics include.</p><blockquote><em>Domestic Manufacturing: Turkey has a robust pharmaceutical manufacturing sector, with numerous local companies producing a wide range of medications. The country aims to increase domestic production to reduce reliance on imports and enhance the competitiveness of its pharma industry.</em></blockquote><blockquote><em>Generics and Biosimilars: The generics market is significant in Turkey, with a focus on cost-effective alternatives to branded drugs. Biosimilars, highly similar versions of biologic drugs, have gained prominence in recent years, offering affordable treatment options for patients.</em></blockquote><blockquote><em>Market Access and Affordability: Turkey’s government strives to ensure access to essential medications for its population. The Social Security Institution (SGK) provides coverage for a broad range of pharmaceutical products, making them affordable for patients.</em></blockquote><h3>The Importance and Impact of Patents</h3><p>Due to the importance of patents, innovative companies carefully prepare patent applications and follow legal processes. Moreover, once a patent expires, competition increases, and new products can enter the market. The pharmaceutical industry has the second-highest research and development spending, following the aerospace and space technology sector. The cost of introducing a new drug to the market is around 300 million US dollars, with a 50% chance that the resulting product will be ineffective. Therefore, innovative companies need incentives like patents to cover these costs.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/700/0*mTQpXvMNEHMOESV_.jpeg" /></figure><h3>Price Controls and Competition</h3><p>Price controls and related regulations make it difficult to accurately assess the dimensions and structure of competition in the pharmaceutical industry. The prevalence of price controls can create the perception that competition is not possible in the industry, but this is not the case. In the US drug market, where prices are not controlled, and manufacturers freely set prices, competition mainly occurs within the framework of price competition.</p><h3>Price Competition</h3><p>Price competition in the pharmaceutical industry is a process that occurs at different stages and dimensions. Original drugs, first produced under patent protection, may operate as a monopoly for a short period. However, competition in the pharmaceutical industry begins during the research and development stage and intensifies within two years, as different active ingredients for the same or similar diseases’ treatments are introduced. At this stage, competition resembles the conditions in markets with heterogeneous products created by different active ingredients.</p><blockquote><em>Therefore, companies operating in the pharmaceutical industry must understand the importance and duration of patents and make their applications correctly. Patents help innovative companies protect their investments, recover their costs, and fund future research and development activities. The pharmaceutical industry has the second-highest research and development spending, following the aerospace and space technology sector. The cost of introducing a new drug to the market is around 300 million US dollars, with a 50% chance that the resulting product will be ineffective. Therefore, innovative companies need incentives like patents to cover these costs.</em></blockquote><p>Although price control regulations may be considered to negatively affect competition in the pharmaceutical industry, competition primarily occurs within the framework of price competition in the US drug market, where prices are not controlled. Price competition in the pharmaceutical industry is a process that occurs at different stages and dimensions. Original drugs, first produced under patent protection, may operate as a monopoly for a short period. However, competition in the pharmaceutical industry begins during the research and development stage and intensifies within two years, as different active ingredients for the same or similar diseases’ treatments are introduced. At this stage, competition resembles the conditions in markets with heterogeneous products created by different active ingredients.</p><h3>The Glaxo-Wellcome Merger</h3><p>In1995, Glaxo and Wellcome filed a merger application, which was reviewed by the European Union Competition Commission. During the review process, it was determined that Glaxo had the largest market share in the injectable migraine medication market, while Wellcome did not operate in this area. However, both companies were found to be conducting research and development activities on an orally administered migraine medication with similar effects. As a result, the European Union Competition Commission imposed certain conditions before approving the merger to address the risk of reduced competition and increased prices in the migraine medication market. These conditions included the sale of one of the migraine medication research and development activities or related patents and Glaxo’s withdrawal from shared research and development activities with another pharmaceutical manufacturer.</p><p>The merger application details were reviewed by the European Union Competition Commission and a decision was reached in 1996. The decision was further reviewed by the European Union Competition Court and approved in 1998. This case demonstrates that mergers in the pharmaceutical industry can be subject to conditional permissions by competition authorities and that research and development competition can also have an impact on merger applications.</p><blockquote><em>During a merger, the potential entry of a business into the relevant market, which is not currently active in the market but can enter the market due to its position, indicates that the impact on the businesses in the market will be eliminated by entering the market through the merger. With the elimination of this effect, the businesses in the market will feel less competitive pressure, and the market power of dominant businesses will increase further. Although this theory mainly concerns businesses operating in the same product market but in different geographic markets, it has also been raised concerning businesses operating in related or adjacent markets.</em></blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/700/0*9t_sAAE5P7mt4FVx.jpeg" /><figcaption>European Union Competition Court</figcaption></figure><p>Glaxo Wellcome, a UK-based pharmaceutical company, focused on producing pharmaceutical products primarily for treating asthma and HIV/AIDS. In 1991, it was the third-largest pharmaceutical company by revenues and held around 4 percent of the market share in the industry. On the other hand, SmithKline Beecham, another UK-based company, was engaged in the global production of medicines. In 2000, a merger between SmithKline Beecham and Glaxo Wellcome took place in the UK, resulting in the formation of GlaxoSmithKline (EvaluatePharma, 2000). Glaxo Wellcome merged its operations with a total value of $75.7 billion.</p><p>The European Commission and the United States Federal Trade Commission (FTC) reviewed the merger proposal (Markham, 2002). They determined that the merger would not negatively impact the competition level in the industry. There were several objectives behind the merger, including addressing issues such as R&amp;D pipelines and costs, drug reimbursement, political pressure for reducing prices, and patent expiration. The goal was to reduce or eliminate these issues while achieving and sustaining a significant market share.</p><blockquote><em>As a result of the merger, the combined entity became a leader in the global pharmaceutical market. The merger also led to a significant improvement in financial performance and spurred innovation in medicine production. Moreover, it expanded the company’s operational network in the global market, meeting the growing demand for drugs. This benefited all stakeholders (Glader, 2006). The merger also resulted in increased competition, motivating other global and national pharmaceutical companies to reduce operational costs while maintaining product and service quality (EvaluatePharma, 2000).</em></blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/0*W4zxREpMjQe5oEvl.jpeg" /><figcaption>United States Federal Trade Commission</figcaption></figure><h3>Conclusion</h3><p>To ensure healthy competition in the pharmaceutical industry, it is essential to implement price controls correctly and provide free market conditions. While patents are important tools for encouraging innovation, legal processes must be followed, and misuse should be prevented. Healthy competition encourages innovation and development activities in the sector, ultimately improving patients’ quality of life.</p><h3>Authors</h3><p>Egemen Can İkiok — Yeditepe University School of Law</p><p>Dogukan Dinc — Istanbul University School of Business, Business Insights &amp; Analytics Intern @ Sanofi</p><h3>References</h3><p><em>Competition Authority. (1999). Preliminary Investigation Report on the Pharmaceutical and Chemical Industry Employers Association (D1/2/M.Ö.-98/8). Ankara, Turkey.</em></p><p><em>Su, K.T. (2003). The Measurement of Market Power in Determining the Dominant Position of Enterprises in Competition Law. Ankara, Turkey.</em></p><p><em>Karakoç, H.D. (2005). Price Competition in the Pharmaceutical Industry. Ankara, Turkey.</em></p><p><em>Abu Sufian, M., &amp; Rana, S. M. S. (2019). The effects of merger on competition: evidence from SmithKline Beecham and Glaxo Wellcome. International Journal of Business and Society, 20(2), 508–519.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4c92f85913f1" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why machine learning is so popular today? Why we call it “Data” Science]]></title>
            <link>https://medium.com/@dogukan.dinc/why-machine-learning-is-so-popular-today-why-we-call-it-data-science-95d6a7eb7ee0?source=rss-d29e23a4b0dd------2</link>
            <guid isPermaLink="false">https://medium.com/p/95d6a7eb7ee0</guid>
            <category><![CDATA[programming]]></category>
            <category><![CDATA[machine-learning]]></category>
            <category><![CDATA[data-science]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[business]]></category>
            <dc:creator><![CDATA[Dogukan Dinc]]></dc:creator>
            <pubDate>Mon, 20 Feb 2023 17:57:59 GMT</pubDate>
            <atom:updated>2023-02-20T17:57:59.874Z</atom:updated>
            <content:encoded><![CDATA[<p>Machine learning and its usage areas have a wide range, in this article I will write about machine learning algorithms and their applications in the field of business.</p><p>First of all, let’s get some general knowledge about machine learning algorithms. According to IBM, machine learning is is a branch of artificial intelligence (AI) and computer science which focuses on the use of data and algorithms to imitate the way that humans learn, gradually improving its accuracy.” means. In this context, there are two basic concepts that we see.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*I6rdoY_FZCCHnxIQ_42Hkw.jpeg" /></figure><blockquote>Data &amp; Algorithm</blockquote><p>As we mentioned before, machine learning is a methodology that feeds on some kind of data and does not need constant reprogramming. Here we need to focus on the concept of nutrition from data. Machine learning is not a new concept. It existed in earlier times. This term, whose origins date back to the 1960s, was intended to radically change human life. But there was a big obstacle in front of him. Big data…</p><p>With today’s economy and technology, we are producing data at an enormous scale. From the car we ride to the music we listen to, the clothes we choose, the food we eat, the way we walk, the water brand we use, our demographic information, our breathing frequency, our reproductive habits, our disease frequency, our attitudes at school, our performance at work, our budget, and hundreds of thousands of data types that we can’t count yet today’s database management technologies, it can now be stored and managed very easily.</p><p>To understand big data, we need to understand its 5 V’s.</p><ul><li><strong>Variety :</strong>Most of the data produced has different formats. Data generated from different sources contain different types of data.</li><li><strong>Volume: </strong>In the past 10 years, the data volume has tended to increase more than 50 times, but the expenditures for data storage technologies have increased by 2 times. This situation reveals the importance of managing the obtained data correctly and efficiently.</li><li><strong>Velocity: </strong>Increasing technological opportunities day by day cause the amount of data obtained, the number and variety of transactions to be made to increase in the same way. Thus, we started to produce more data faster.</li><li><strong>Value: </strong>The most important component about big data is value. The data obtained and processed is meaningful as long as it adds value to the organization. For this reason, it is a priority to construct the analysis and simulations of big data correctly and to benefit the organization using big data.</li><li><strong>Verification: </strong>Another issue that has come to the fore in recent years regarding data has been data security and accuracy. By whom and under what conditions the obtained data will be viewed, and which of these data should be kept confidential are issues that need to be studied carefully.</li></ul><p>This is where the importance of big data comes into play. While the size of observable data that we produced before was quite limited, in the 21st century, data is pouring out from every corner. Apart from the areas I have mentioned, the business world has also had its share of data. Big data helps companies to make the right decisions and develop strategies by understanding customer behavior. After the data in hand is made usable (normalization, stardization, etc.), the relationships between these data are examined by using machine learning algorithms and the connections between them can be revealed. In this way, it is possible to foresee the consequences of the decisions to be taken. With different scenarios created by changing the features in various situations in the data, the reactions to different situations can be examined.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=95d6a7eb7ee0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Introduction to Asset Bubbles]]></title>
            <link>https://medium.com/@dogukan.dinc/introduction-to-asset-bubbles-c6056b70f956?source=rss-d29e23a4b0dd------2</link>
            <guid isPermaLink="false">https://medium.com/p/c6056b70f956</guid>
            <category><![CDATA[cryptocurrency]]></category>
            <category><![CDATA[finance]]></category>
            <category><![CDATA[stock-market]]></category>
            <category><![CDATA[trading]]></category>
            <category><![CDATA[economics]]></category>
            <dc:creator><![CDATA[Dogukan Dinc]]></dc:creator>
            <pubDate>Thu, 16 Feb 2023 17:26:14 GMT</pubDate>
            <atom:updated>2023-02-18T08:24:38.442Z</atom:updated>
            <content:encoded><![CDATA[<p>Everything has a value. This value can be measured or not. The important thing is to make sure we are estimating the right value. A short description; Asset bubbles are the buying and selling of goods, products, assets and commodities with an overvalue that is more inflated than the real value.</p><p>I planned this series of articles about asset bubbles in 3 parts. This article you are reading now is the first article of the series and includes general information and introduction to the subject. Here are the chapters I’m planning to write:</p><blockquote>Part 1,</blockquote><ul><li>Definitions and examples of asset bubbles</li><li>The history of asset bubbles</li><li>Asset bubbles before the 20th century</li></ul><blockquote>Part 2,</blockquote><ul><li>The formation of the modern financial system</li><li>Asset bubbles in the early 21st century</li></ul><blockquote>Part 3,</blockquote><ul><li>2008 Mortgage Crisis and the financial system after</li><li>Pandemic and current asset bubbles</li><li>What awaits us in the future?</li></ul><p>So let’s get started.</p><p>These price (value) bulges, which we often describe as asset bubbles, are basically a fault of the financial system. Because the value of (almost) everything has been determined by money since the day the money-economy existed. As we know, the laws of supply and demand apply to the formation of prices. Economics considers people as “rational” at the points where consumption-production, supply-demand balances pass and occur. This view argues that most things whose value is determined by supply and demand are actually priced reasonably. Because some economists argue that asset bubbles do not actually exist, because an asset priced by supply and demand is already priced at the market equilibrium point. However, in some cases, we can see that this thesis is invalid. For example, stocks have a market value and a book value. We make use of some ratios (MV/BV, P/E, MV/EBITDA) while valuing the stocks whose value is determined in organized exchanges. These values give us an opinion about the stock being traded. You must have heard phrases such as “The price is too high”, “It cannot be bought at this price”, “This security ain’t worth it”. These measurements can be made in stock markets operating with a market economy. So what about the other markets? For example, real estate market, commodity &amp; FX market, and cryptomoney market. In fact, it is possible to make valuations in other markets as well. For example, there is a “Theoretical Rate” in exchange rates, different from the market rate. This valuation, which is based on inflation, current account deficit and other economic facts, is often different from the market price. Especially in fragile economies, this difference becomes wider and is suitable for speculation / manipulation.</p><p>Take the real estate market, for example. There is “Fair Value” as a base price policy set by the government for the value of real estate. When you sell your house below this value, the relevant institution will immediately initiate an investigation. So, can we say anything definite about asset bubbles when there are so many different valuations in so many different markets? Of course not! For example, let’s assume that house prices are too high and people with average purchasing power cannot afford this price. According to a market economy, this is a result of supply and demand. There will definitely be people or institutions that will buy those houses. Because if not, prices should come down. What if it doesn’t fall? What if homeowners don’t rush to sell their homes? What if liquidity isn’t a priority? What if the government doesn’t intervene? All these questions pave the way for the formation of asset bubbles.</p><p>Let’s take a look at the history of asset bubbles. The first known bubble of existence (which can be properly studied) in history is the Tulip Bubble, also known as the Tulip Frenzy. Europeans, who received the tulip culture from the Ottomans, spread this culture. This event takes place in the Netherlands in the 17th century (late 1630s). After the tulip bulbs were seen as more than their worth by both the public and the market, the prices increased unreasonably. It has reached such high points that a single tulip is worth the price of a house. 20th century and previously known major asset bubbles; South Sea Bubble (1720), Mississippi Bubble (1720), US Stock Bubble of the late 1920s (1929), Japan Real Estate Bubble (1986–1991). While organized stock markets have not become that widespread, the occurrence of such asset bubbles may of course be a sign that asset bubbles exist and that the market (system) is a failure.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*qxwQ8Lh34GLnfQo5nPO_gA.jpeg" /><figcaption>Tulip Price Index (1636–1637)</figcaption></figure><p>One of the big bubbles that should be emphasized is undoubtedly the collapse of the US Stock Exchange in 1929. This crisis, which was the result of many other macro-financial reasons, the instability of the world economy, and the bubble in the stock market, is engraved in history. Due to its location, the USA was in a geography far from World War I and sold weapons to other countries. This naturally led to prosperity in the country. All the people almost flocked to the stock market and piled all their money into companies. Then one Thursday, the stock market crashed. Companies and banks went bankrupt. People were unemployed. At this point, I can’t think of the following sentence used by stockbrokers: “Buy it when they sell, sell itwhen they buy.”</p><p>Finally, let’s come to the Japan Real Estate Bubble (1986–1991). This crisis, which emerged when the Bank of Japan (BOJ) increased interest rates and contracted loans in order to prevent the endless rise of Real Estate prices in Japan and the Japanese Stock Exchange (Nikkei 225), is very important. Because the point here is the effect of this crisis on the financial system is that companies have plenty of securities and real estate on their balance sheets. While securities and real estates lost value, deterioration occurred in company balance sheets and collapses began. Home prices were so high that it was possible to buy the whole real estate market in the USA (at the theoretical price) with only the whole real estates in Tokyo.</p><p>In this article, I tried to present you an introduction and history about asset bubbles. In my other articles, I will continue to write about the financial system and asset bubbles after 2000. I wish you a pleasant and healthy week.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c6056b70f956" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Derivatives Markets]]></title>
            <link>https://medium.com/@dogukan.dinc/derivatives-markets-bff90d0407dc?source=rss-d29e23a4b0dd------2</link>
            <guid isPermaLink="false">https://medium.com/p/bff90d0407dc</guid>
            <category><![CDATA[trading]]></category>
            <category><![CDATA[derivatives]]></category>
            <category><![CDATA[economics]]></category>
            <category><![CDATA[mathematics]]></category>
            <category><![CDATA[finance]]></category>
            <dc:creator><![CDATA[Dogukan Dinc]]></dc:creator>
            <pubDate>Wed, 15 Feb 2023 12:00:19 GMT</pubDate>
            <atom:updated>2023-02-15T12:02:20.082Z</atom:updated>
            <content:encoded><![CDATA[<p>Capital markets are like a river. You can swim in this river, you can travel as you wish, you can drink its water if you want, but if you don’t know, you can drown.</p><p>Today’s opportunities and technologies have driven the capital markets and the financial world in a very different direction. This drag spread to all branches and circles. This structure, which progressed over time, was put into service in line with various purposes, especially with the aim of minimizing risks. These services have helped economies move more healthily and that uncertain risk factors do not take up too much of the agenda. While the financial investments carried out in the past were monthly or annual, now the investments have started to be shorter-term or even hourly. These different concepts were called “trading”, and “scalping” when appropriate. With the increase in speculative appetite, capital markets have evolved into very different points. Capital markets have now become a “commodity”. Large-scale capital owners and organizations that wanted to benefit from this formation added capital to their own capital through speculative transactions. Of course, these processes continued in different ways over the years. There was a need for more developed markets than the markets that we previously knew as the spot market, where payment and trading transactions occur at the same time. These needs gave birth to derivatives markets. Markets where payment and trading take place on a specified date and at a specified price were also called futures markets. “Derivative Markets” started to operate for these transactions. Various markets and controls were established. For our country, these transactions first became TurkDEX, then VIOP (Futures and Options Market) within the BIST. Derivatives Markets are highly developed abroad, especially in the USA. The USA, which has taken these steps since the 19th century, has a much more developed structure in the field of finance thanks to formations such as CBOT (Chicago Board of Trade) established in Chicago.</p><p>If we can have an idea about derivative products and derivative markets and the history of these instruments, let’s talk about the purpose and details of derivative products and their markets. The fields of derivative products, which are basically used for three main purposes, can be listed as follows.</p><ul><li><em>Hedging</em></li><li><em>Speculation</em></li><li><em>Arbitrage</em></li></ul><p>Hedging is basically the technique used to hedge against fluctuations and volatility in financial markets. For example, let’s say that you are a business that imports dollars and you have dollar debt, opening a suitable “long” position in (USD/TRY) futures contracts will help you protect you against this financial risk. Assuming you are a company that exports in Euro and you have Euro liabilities, opening a “short” position in (EUR/TRY) futures can protect you against possible risks.</p><p>At the points where the real sector meets the financial sector, this is one of the hedging methods taken against the risk of blocking or blocking some of the “veins” that provide resources to the company. For example, you want to produce using any raw material. However, the value of the commodity you need seems to rise in the markets due to various reasons (rule, shortage, deprivation or expectations). Such situations are one of the reasons that increase the use of risk management and derivative products and contribute to the formation of financial risk units of companies.</p><p>Since derivative markets are very voluminous, deep and diverse, it is also possible to profit from the volatility that occurs. For this reason, there are many investors who use various leverages in the derivative markets and trade in the direction of “high risk — high gain” or “high risk — high loss”. The presence of these investors provides both volume and depth to the markets. However, uncontrolled and unlimited use of derivatives can cause bubbles and even crises. (2008 Global Financial Crisis)</p><p>Another usage area of derivative products is to make profit by taking advantage of arbitrage. Arbitrage is a way of making a profit by buying the same type of product or security in the cheaper market and selling it in the expensive market. However, this is not always the case. At the point where supply and demand are balanced, the arbitrage opportunity ends, because the market balances itself. Because you need to act early and be fast in order to make arbitrage. Considering that today’s operations are performed in milliseconds by algorithms and robots, this job is quite difficult.</p><p>Derivative markets also include forward, futures, options and swap transactions. These, too, are a kind of futures and financial instruments traded today, with delivery in the future.</p><p>Forward transactions are futures transactions that are traded on unorganized exchanges, that is, based on the agreement between the buyer and the seller on the basis of price, time and quantity.</p><p>Option contracts, on the other hand, are standardized contracts on the basis of price, maturity and quantity, traded on organized exchanges.</p><p>The most widely used and known option pricing method is the Black-Scholes Option Pricing Technique, which was mentioned in the article “the pricing of options and corporate assets” written by Fisher Black and Myron Scholes in 1973, and is still widely used.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/493/1*TtAzsNtFo0vUWUy_VfDYEw.png" /><figcaption>Black-Scholes Option Pricing Model</figcaption></figure><p>For the buyer, there are several types of options and they are Call and Put options. Apart from these, there are two types of options. American options and European options. In European type option contracts, the holder of a “long” position can exercise the option only within the time period determined on the expiry date. In American type options, the holder of the “long” position can exercise the option any time between the date of purchase and maturity.</p><p>Swap transactions, on the other hand, are a transaction in which both parties agree to exchange their payments in a certain period of time. Swap agreements, which we hear a lot these days, together with the name of the CBRT, are such an agreement.</p><p>Of course, factors such as Capital Market Law and Commercial Law, which protect such systems, ensure the formation of healthier capital markets and more accurate working economic wheels. While orderly and harmoniously functioning markets give life to economies, unregulated and uncontrolled markets can cause crises with disastrous results. At this point, authorities and regulatory bodies have to accelerate their efforts to bring the global economic system to more optimal levels.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bff90d0407dc" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>